

Q2 2025 Earnings Presentation

August 14, 2025





Disclaimer

This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Forward-looking statements and information are often, but not always, identified by the use of words such as "appear", "seek", "anticipate", "plan", "continue", "estimate", approximate", expect", "may", "will", "project", "predict", "potential", "targeting", "intend", "could", "might", "should", "believe", "would" and similar expressions. Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of the management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.

Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the risks associated with: primary healthcare sector in general; competition; that future results may vary from historical results; the availability and effective integration and operation of management information systems and other technologies; ability to mitigate against cyber security risks; ability to access sufficient capital from internal and external sources; changes in legislation, including but not limited to tax laws; and government regulations. Accordingly, readers should not place undue reliance on the forward–looking statements, timelines and information contained in this presentation. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this presentation are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events, or otherwise, unless so required by applicable securities laws or the TSX Exchange. The forward-looking statements or information contained in this presentation are expressly qualified by this cautionary statement. The TSX Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this presentation.

The WELL Health Family Tree

WELL Health Technologies Corp. TSX: WELL

CYBERWELL (Future IPO)

Pure-Play Data Protection and Cybersecurity



WELLSTAR (Future IPO)

Pure-Play Provider-Focused Technology Solutions



WELL Canadian Clinics

Pure-Play Tech-Enabled Healthcare Delivery

** WELL Health | CLINIC NETWORK

HEALWELL AI TSX: AIDX

Pure-Play Al, Data Science, and Healthcare Software

HEALWELLAI



WELL Q2 2025 Key Financial Highlights

Q2 Revenue

\$356.7M

+57% Y/Y

Q2 Adj. EBITDA

\$49.7M

+231% Y/Y

Q2 Adj. Gross Margin

Inc. CM Exc. CM

44.5% 43.0%

Q2 Revenue exc. CM Impact¹

\$347.0M

+53% Y/Y

Q2 Adj. EBITDA exc. CM Impact¹

\$40.0M

+166% Y/Y

Q2 FCFA2S

\$11.6M

+34% Y/Y



¹⁾ The impact from Circle Medical revenue deferrals is removed in both Q2-25 and Q2-24

²⁾ WELL Canada Adj. EBITDA is on a 4-wall basis

WELL Q2 2025 - WELL Canada & CRH (Illustrative View)

Excludes HEALWELL and US Digital Patient Services Assets (CM + Wisp)

Q2 Revenue

\$254.2M

Total Growth

Organic

+36%

+20%

Q2 Gross Profit

\$98.5M

CAN GM%

CRH GM%

49%

28%

WELL Canada Revenue

\$131.4M

Total Growth

Organic

+40%

+25%

Q2 Adj. EBITDA¹ \$38.4M

+40% Y/Y

Q2 Adj. EBITDA Margin

15.1%

+50bps Y/Y

WELL Canada Adj. EBITDA²

\$23.0M

+76% Y/Y



¹⁾ This Q2 Adj. EBITDA figure includes full load of shared services and HQ expenses.

²⁾ WELL Canada Adj. EBITDA is on a 4-wall basis and excludes shared services expenses.

WELL Q2 2025 Operational Highlights¹

4,300+

Providers in WELL's Clinic Network 42,000+

Unique Providers supported by WELL's Technology

2.7M+

Total Care Interactions +29% YoY (+19% organic)

1.6M+

Patient visits +24% YoY (+14% organic) 1.06M

CAN patient visits in a single quarter

+38%

YoY CAN patient visit growth (+12% organic)



Q2-2025 Earnings – Additional Topics to be Covered

Key updates on the following:

- 1. Canadian Clinics Update
- 2. WELLSTAR
- 3. HEALWELL AI
- 4. Strategic Alternatives Processes for US Assets




WELL Canadian Clinics Financial Performance





WELL Canadian Clinic M&A Track Record

Deal and Effective¹ Total Consideration/Sh. EBITDA Multiples



Total Consideration	\$22.4M	\$230.3M	\$5.8M	\$7.4M	\$14.8M
Number of Transactions	6	5	4	6	10
Acquired Revenue	\$39M	\$105M	\$20M	\$57M	\$53M
Adj. EBITDA Growth ⁴ (%)	76%	107%	234%	nmf	47%

\$280.7M	\$64.5M	
31	30	
\$273M	\$173M	
101%	131%	




¹⁾ Effective multiple is based on H1-2025 Run rate Adj. EBITDA. One time retro payments in Q2-2025 are included as reported and have not been annualized.

²⁾ Excludes one-time bad debt expense.

³⁾ The sum of Adj. EBITDA for the 2023 cohort of deals at close was negative.

⁴⁾ Adj. EBITDA growth excludes one-time clinic transformation costs and shared services.

WELL Providers Are Seeing more Patients





WELL Canada Experiencing Accelerating Growth

WELL Canada

Quarterly Revenue Growth



WELL Canada Quarterly Adj. EBITDA Growth






WELL Canada Fast-Tracks to \$100M+ Adj. EBITDA

Recent M&A activity and strong organic growth have accelerated WELL Canada's timeline—shifting the \$100M+ annualized Adj. EBITDA run-rate target from the end of 2026 to mid-2026.



Expected Adj. EBITDA annualized runrate by mid 2026⁽¹⁾





WELL's Current Canadian Clinic Market Share

WELL is Canada's largest network of outpatient clinics - yet accounts for only ~1.6% of patient visits in the country

By Patient Visits

WELL Canadian Clinics vs Competitors





Canadian Clinic Recent M&A Activity

Q1-2025 Q2-2025 Q3-2025 To Date

+11 Clinics

4 transactions

+3 Clinics

3 transactions

+4 Clinics

4 transactions

+\$31.5M

Annual Revenue

+\$8.0M

Annual Revenue

+\$15.1M

Annual Revenue

+71 Providers

Total Canadian Clinics

+46 Providers

Total Canadian Clinics

+72 Providers

Total Canadian Clinics



M&A Pipeline

WELL continues to execute on a robust pipeline, driving growth and sustaining strong operational momentum.

Under LOI: Canadian Clinics

\$48M Revenue

7Signed LOIs

25 Clinics

Under LOI: Total WELL¹

\$134M Revenue

15
Signed LOIs

Total WELL Pipeline

~\$440M Revenue

35+
Targets Engaged

110+
Clinics



¹⁾ HEALWELL AI's pipeline and LOIs are included

²⁾ The Total WELL Pipeline includes potential deals that are either under LOI or in the pre-LOI stage.

WELL's Future Canadian Clinic Market Share

Long-term vision to significantly increase WELL's national market share through capital efficient growth


WELL Path to Expansion

Commentary	
------------	--

	Current	Future	
Annual Revenue	>\$400M	\$4.5B+	
EBITDA	>\$50M	\$650M+	
Clinics	222	1,400+	
Patient Visits	4M+	40M+	
Est. Market Share	1.6%	8-10%	

- Scalable acquisition engine in place
- Robust clinic pipeline supports accelerated expansion in the near-term
- Al workflows in clinic acquisition and integration processes condenses timelines
- Proven team with experience optimizing hundreds of clinic sites

WELLSTAR >> Continued Financial Out-performance



¹⁾ WELLSTAR's revenue in the chart includes intercompany revenues.



²⁾ WELLSTAR's Adj. EBITDA excludes Shared Services expenses.


WELLSTAR >> Leading the Country in "Provider-tech"

EMR	3,700+ Clinics served	~16,000 Practitioners	Primary care and specialist-based EMR platforms enable practitioners to better manage their patient interactions and improve their encounters.
Digital Health Apps	55+ Digital apps	~25,000 Practitioners	The largest ecosystem of integrated and AI-enabled applications for automating day-to-day clinical tasks and workflows.
Billing & Practice Management	1,500+ Clinics served	~13,800 Practitioners	Optimizes insured and uninsured medical billing and infrastructure management to maximize provider revenue and reduce tech downtime.

HEALWELL AI >> A Transformational Quarter







Commentary

- Q2 annualized run-rate revenue of \$160 million
- Achieved first quarter of positive Adj. EBITDA
- Transition to pure-play SaaS and services company
- Orion acquisition positions the Company with global footprint with over 70 customers operating in 11 countries




Strategic Alternatives Processes for US Assets








Q2-2025 Financial Highlights <> Record Revenue & Adj EBITDA



Adj. EBITDA






⁽¹⁾ Q2-2024 figures were restated.

⁽²⁾ CM Net Impact represents the impact of Circle Medical's deferred revenue adjustments on the given financial metric for the period shown.


Q2-2025 Financial Highlights <> Record Adj. Net Income



⁽¹⁾ Q2-2024 figures were restated.



Q2-2025 Financial Highlights – FCFA2S



Outlook: 2025 and Beyond

2025 Guidance: Upper half of: \$1.40-1.45B Revenue \$190-210M Adj. EBITDA HEALWELL
Consolidation of
\$40.5M Revenue in Q22025

WELL Canada >25% Adj. EBITDA Growth⁽¹⁾ for 2025

2025 Guidance exc. CM
Upper half of:
\$1.35-1.40B Revenue
\$140-160M Adj. EBITDA

Strategic Alternatives
Being Executed on for All
US Care Businesses

WELL Canada
2-Yr Target⁽¹⁾ of
>\$800M Revenue
>\$100M Adj. EBITDA

Contact

Hamed Shahbazi
CEO, Chairman & Founder
hamed@well.company

Tyler Baba Investor Relations investor@well.company

www.well.company 550-375 Water Street Vancouver, BC V6B 5C6 Canada

